Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BLIS TechnologiesNZSE:BLT +6.25% PB Ratio is 1.70 as of Jul. 22, 2026, which is 70% below its 10-year median of 5.59. The stock has 4 warning signs investors should review. Among 1,229 Biotechnology companies, BLIS Technologies ranks better than 68.92% on this metric.
The historical rank and industry rank for BLIS Technologies's PB Ratio or its related term are showing as below:
NZSE:BLT'
s PB Ratio Range Over the Past 10 Years
Min: 1.4 Med: 5.59 Max: 23.33
Current: 1.7
During the past 13 years, BLIS Technologies's highest PB Ratio was 23.33. The lowest was 1.40. And the median was 5.59.
NZSE:BLT's PB Ratio is ranked better than 68.92% of 1229
companies
in the Biotechnology industry
Industry Median: 2.82
vs NZSE:BLT: 1.70
During the past 3 years, the average Book Value Per Share Growth Rate was 3.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 10.40% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 14.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of BLIS Technologies was 49.40% per year. The lowest was -44.20% per year. And the median was -7.20% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
BLIS Technologies PB Ratio Related Terms
BLIS Technologies PB Ratio Historical Data
* Premium members only.
The historical data trend for BLIS Technologies's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BLIS Technologies's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BLIS Technologies PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BLIS Technologies's PB Ratio distribution charts can be found below:
* The bar in red indicates where BLIS Technologies's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
BLIS Technologies (NZSE:BLT) has a PB Ratio of 1.70 as of Jul. 22, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BLIS Technologies and its competitors. This is 70% below median its historical median of 5.59. Over the past decade, BLIS Technologies' PB Ratio has ranged from 1.40 to 23.33. According to the industry distribution chart, BLIS Technologies ranks #382 out of 1229 companies in the Biotechnology industry, placing it in the top 31.1%.
Is BLIS Technologies' PB Ratio too high?
BLIS Technologies' current PB Ratio of 1.70 is 70% below median its 10-year median of 5.59. Over the past 10 years, this metric has ranged from a low of 1.40 to a high of 23.33. The Biotechnology industry median PB Ratio is 2.82. BLIS Technologies' value of 1.70 is 39.7% below this industry median. Based on the distribution chart, BLIS Technologies ranks #382 out of 1229 companies in the Biotechnology industry, which is above the industry midpoint.
How does BLIS Technologies' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BLIS Technologies ranks #382 out of 1229 companies for PB Ratio. This puts BLIS Technologies in the upper half of its industry. The industry median PB Ratio is 2.82. BLIS Technologies' value of 1.70 is 39.7% below this benchmark. Historically, BLIS Technologies' own PB Ratio has ranged from 1.40 to 23.33 over the past decade. While the company's 10-year median is 5.59 vs. the industry median of 2.82, BLIS Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.82, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BLIS Technologies's current PB Ratio of 1.70 is 39.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BLIS Technologies and its competitors. For the Biotechnology industry, the median PB Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BLIS Technologies's current PB Ratio is 1.70, which is 70% below median its own 10-year median of 5.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLIS Technologies stock overvalued right now?
Based on GuruFocus' analysis, BLIS Technologies (NZSE:BLT) is currently considered Modestly Undervalued. The stock's GF Value™ is NZ$0.02, compared to a current price of NZ$0.02 — trading 15% below its estimated fair value. The current PB Ratio is 1.70, which is 70% below median its 10-year median of 5.59 and 39.7% below the Biotechnology industry median of 2.82. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For BLIS Technologies (NZSE:BLT), the current PB Ratio is 1.70 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BLIS Technologies Ltd is engaged in developing oral probiotics. The company markets strains of probiotic bacteria BLIS K12, BLIS Q24, and BLIS M18, which occur naturally in the oral cavity. Its product portfolio consists of probiotic serum, Teeth and gums lozenge, fresh breath lozenge, and immune lozenge. Geographically, the company derives a majority of its revenue from North America. The company also generates a small portion of revenue from Non-core business, which includes grants and interest revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NZSE:BLT has been successfully added to your 
